Aspen Pharmacare (OTCMKTS:APNHY) & Taysha Gene Therapies (NASDAQ:TSHA) Critical Contrast

Aspen Pharmacare (OTCMKTS:APNHY) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Aspen Pharmacare and Taysha Gene Therapies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspen Pharmacare	0	0	0	0	0.00
Taysha Gene Therapies	1	0	10	1	2.92

Taysha Gene Therapies has a consensus target price of $10.30, indicating a potential upside of 145.53%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Aspen Pharmacare.

Insider & Institutional Ownership

77.7% of Taysha Gene Therapies shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Aspen Pharmacare and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspen Pharmacare	N/A	N/A	N/A
Taysha Gene Therapies	-1,144.97%	-67.26%	-42.14%

Volatility and Risk

Aspen Pharmacare has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.

Valuation and Earnings

This table compares Aspen Pharmacare and Taysha Gene Therapies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspen Pharmacare	$2.39 billion	1.03	-$59.67 million	N/A	N/A
Taysha Gene Therapies	$8.33 million	137.95	-$89.30 million	($0.33)	-12.71

Aspen Pharmacare has higher revenue and earnings than Taysha Gene Therapies.

Summary

Taysha Gene Therapies beats Aspen Pharmacare on 8 of the 13 factors compared between the two stocks.

About Aspen Pharmacare

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.